RBC Global Healthcare Conference: Rubedo Life Sciences is the first company to be in the clinic with an GPX4 modulator. They are announcing data today for the first time in actinic keratosis
- 60 minutes ago
- 1 min read
CEO Frederick Beddingfield says they saw a 46% reduction in the AK count in 4 weeks in the first 18 actinic keratosis patients evaluated. He describes the science and what is next.







.png)
